Consolidated loss widens 38% YoY to ₹106.9 Cr as Phase 3 trial R&D spend climbs 43%
PAT -38.3% YoY · revenue +30.4% · margins compressing
₹1.2 Cr
+30.4% YoY
₹-106.94 Cr
-38.3% YoY
-1348.55%
-1248.6pp YoY
₹-3.77
Suven Life Sciences posted a consolidated net loss of ₹106.94 Cr for Q2 FY27 (quarter ended 30 Sep 2026), widening 38.3% year-on-year from ₹77.31 Cr, with basic EPS at -₹3.77 versus -₹3.48 a year ago. There are no exceptional items on either side of the comparison, so this is a clean YoY read with no adjustment needed. Operating revenue remains practically nil at ₹1.20 Cr — up 30.4% YoY but down 66.4% QoQ — underscoring that this is a pre-revenue, clinical-stage biopharmaceutical; the ₹6.73 Cr of "other income" sitting in the P&L is investment/interest income on the company's cash and mutual-fund book, not operating income.
Q2 FY-2027 vs prior quarters
Conventional margin ratios (NPM/OPM) aren't meaningful here given the near-absent revenue base; the real driver is R&D intensity. Consolidated R&D expense rose 42.7% YoY to ₹100.30 Cr (from ₹70.32 Cr) as the company ran parallel Phase 3 programs for masupirdine (Alzheimer's-related agitation) and samelisant (narcolepsy), pushing total consolidated expenses up 40.1% YoY to ₹114.88 Cr. Sequentially, expenses actually fell 17.2% QoQ and the loss narrowed 16.2% QoQ from ₹127.61 Cr in Q1 FY27 — a step-down in quarterly trial-cost intensity rather than a margin improvement, and since YoY is the primary lens here, the loss trajectory is still structurally widening as more trials run concurrently.
The stock went into the print at ₹272, down 12% over the past month of trading.
Standalone and consolidated numbers diverge sharply enough that readers need the context: standalone net loss is just ₹16.38 Cr against the ₹106.94 Cr consolidated figure. The gap sits almost entirely in the US subsidiary, Suven Neurosciences Inc., which the auditors' limited-review report separately notes carried a standalone quarterly net loss of ₹90.53 Cr — that is where the bulk of Phase 3 clinical costs for the CNS pipeline is booked. No formal management guidance exists on record, and a search turned up no analyst/street consensus estimate for this specific quarter, so both vs-guidance and vs-street read as unknown rather than assumed. Management's own framing, per its news release, is clinical-progress-led rather than financial: SUVN-502 (masupirdine) completed Phase 3 patient enrollment for agitation in Alzheimer's dementia with topline data targeted for Q2 calendar-2027; SUVN-G3031 (samelisant) Phase 3 for narcolepsy is in progress; SUVN-911 (ropanicant) completed its US Phase 2B "with successful outcome" and targets global Phase 3 initiation in Q2 calendar-2027; and SUVN-D4010 (usmarapride) began a Phase 2 proof-of-concept study for cognitive dysfunction in October 2026.
W1
Masupirdine (SUVN-502) Phase 3: last-patient-last-visit targeted Q1 calendar-2027, with topline data potentially in Q2 calendar-2027.
W2
Ropanicant (SUVN-911): global Phase 3 program initiation targeted for Q2 calendar-2027 after a successfully completed US Phase 2B.
W3
₹320.01 Cr of unutilized preferential-issue warrant proceeds (as of 30 Sep 2026) — watch the pace of deployment against the rising R&D run-rate.